2016
DOI: 10.1186/s13063-016-1153-3
|View full text |Cite
|
Sign up to set email alerts
|

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

Abstract: BackgroundIrinotecan is approved and widely administered to metastatic colorectal cancer (mCRC) patients; however, it can cause severe toxicities including neutropenia and diarrhea. The polymorphisms of genes encoding drug-metabolizing enzymes can play a crucial role in the increased susceptibility of cancer patients to chemotherapy toxicity. Therefore, we plan to explore the effect of the genetic polymorphism of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) for irinotecan detoxification in mCRC pat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
28
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 25 publications
(28 citation statements)
references
References 20 publications
0
28
0
Order By: Relevance
“…Newer biologics are now used in all the patients treated for mCRC disease, in association with chemotherapy, in developed countries. However, FOLFIRI is still a highly used, standard backbone chemotherapy in patients with mCRC, and UGT1A1*28 has been demonstrated to impact the toxicity risk also in patients treated with the combination regimens . Only future studies designed to unravel pharmacodynamic interactions between chemotherapy and biologics will assess the impact of *28 genotype on the toxicity management costs of the combination regimens.…”
Section: Discussionmentioning
confidence: 99%
“…Newer biologics are now used in all the patients treated for mCRC disease, in association with chemotherapy, in developed countries. However, FOLFIRI is still a highly used, standard backbone chemotherapy in patients with mCRC, and UGT1A1*28 has been demonstrated to impact the toxicity risk also in patients treated with the combination regimens . Only future studies designed to unravel pharmacodynamic interactions between chemotherapy and biologics will assess the impact of *28 genotype on the toxicity management costs of the combination regimens.…”
Section: Discussionmentioning
confidence: 99%
“…Although various therapeutic strategies have been achieved in cancer-related science and technology, the therapeutic effects of the current treatments are insufficient ( Chen et al, 2017 ). In addition, the treatments are accompanied by significant side effects, such as intestinal mucositis, neuropathic pain, neutropenia, and diarrhea ( Hsieh et al, 2016 ; Yeh et al, 2016 ; de Alencar et al, 2017 ). 5-Fluorouracil (5-FU) and capecitabine, which are widely used to treat CRC, result in undesirable side effects.…”
Section: Introductionmentioning
confidence: 99%
“…genotyping for mCRC treated with FOLFIRI plus bevacizumab [8] and an ongoing prospective randomized controlled clinical trial is conducted to examine the efficacy and safety of aforementioned treatment [10].…”
Section: Discussionmentioning
confidence: 99%